| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918121 | Radiotherapy and Oncology | 2015 | 4 Pages |
Abstract
Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Carlos J. Perez-Torres, Liya Yuan, Robert E. Schmidt, Keith M. Rich, Robert E. Drzymala, Dennis E. Hallahan, Joseph J.H. Ackerman, Joel R. Garbow,